Arne Scheu

Company: Valink Therapeutics

Job title: Chief Executive Officer

Seminars:

Spotlighting Synergy: Embracing a Holistic & High-Throughput Approach to Revolutionise the Development of Fragment-Based Novel Conjugate Drugs 9:30 am

Explore the paradigm shift towards a holistic approach to conjugate design, where equal emphasis is placed on optimizing each component – from payload to linker to targeting binders – to maximize therapeutic efficacy and minimize off-target effects Delve into the innovative methodologies enabling rapid iteration and high-throughput screening of conjugates, allowing for the creation of…Read more

day: Conference Day 1